Acute Human Parvovirus B19 Infection and Nephrotic Syndrome in Patients with Sickle Cell Disease

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4816-4816
Author(s):  
Lynn Quek ◽  
Claire Sharpe ◽  
Neelanjana Dutt ◽  
David Rees ◽  
Sue Height ◽  
...  

Abstract Human Parvovirus B19 (HPV B19) infection has previously been thought to be a trigger of nephrotic syndrome. The virus is associated with significant morbidity in patients with sickle cell disease (SCD) and a major cause of transient red cell aplasia (TRCA). We report three patients with SCD who presented with TRCA secondary to acute HPV B19 infection who subsequently developed significant proteinuria and nephrotic syndrome (NS) on outpatient follow up. There were 37 cases of acute HPV B19 infection in SCD patients admitted to King’s College Hospital between November 2002 and July 2008. 29 cases were in children below the age of 16 years, eight in patients over the age of 16 years. The average age of the cohort was just over 11 years at diagnosis. Three patients developed NS within 4 months of acute HPV B19 infection and TRCA. Two of these patients were aged 17 and 26 years at diagnosis (patient 1 and 2 respectively), whereas the third was a child aged 11 (patient 3). Renal histology demonstrated the collapsing variant of focal segmental glomerulosclerosis (FSGS) in the acute phase of NS in patient 1, a characteristic finding associated with HPV B19-associated nephrotic syndrome. A subsequent biopsy in the same patient two years later demonstrated non-collapsing FSGS and marked interstitial fibrosis. Patient 2 had a renal biopsy performed 4 months after the onset of NS. This demonstrated non-collapsing FSGS, acute sickle nephropathy and significant chronic tubular atrophy. Patient 3 also had a renal biopsy 1 year after her acute HPV B19 infection which demonstrated the cellular variant of FSGS. Patient 1 was treated with immunosuppression and although the NS has improved slowly he continues to have significant proteinuria and progressive renal impairment. Patient 2 has not received immunosuppressive therapy and has also slowly improved from her NS but continues to have significant proteinuria; her estimated GFR has fallen from 169 ml/min to 104 ml/min six months after the acute HPV B19 infection. Patient 3 was treated with corticosteroids with subsequent improvement in serum albumin and symptoms but proteinuria persists with normal renal function. Consistent with previous reports, we observe that NS is a relatively rare complication of HPV B19 infection in young children with SCD (one case in 29 in our cohort). However, two out of eight patients older than 16 years developed this complication. Proteinuria in patients with SCD is common and gradual in onset, and eventually may progress to NS. Nephrotic syndrome of acute onset in adults with SCD is rare, only two cases were observed during a 6-year period among our cohort of over 400 adult patients with SCD. In both cases, they were associated with recent HPV B19 infection. It has previously been noted that acute HPV B19 infection in older patients with HbSC SCD have a more severe clinical course than younger children (Smith-Whitley et al., 2004). Our data, though limited by small numbers in the cohort, suggest that older SCD patients with acute HPV B19 infection may be more susceptible to chronic complications including the development of NS and progressive renal fibrosis. A correct diagnosis of the aetiology of NS is vitally important as the HPV B19-associated condition may not be responsive to corticosteroids, unlike other aetiologies of NS in this age group. It is possible that antiviral therapy may be of benefit in the acute setting but this needs further investigation. Furthermore, immunisation of older children and young adults who are HPV B19-naïve may be effective in preventing an important contributor of chronic renal disease in SCD patients.

2010 ◽  
Vol 149 (2) ◽  
pp. 289-291 ◽  
Author(s):  
Lynn Quek ◽  
Claire Sharpe ◽  
Neelanjana Dutt ◽  
Sue Height ◽  
Marlene Allman ◽  
...  

2014 ◽  
Vol 5 ◽  
pp. 1
Author(s):  
Daniele Don� ◽  
Federica Visentin ◽  
Eleonora Borgia ◽  
Stefania Scanferla ◽  
Carlo Giaquinto ◽  
...  

2002 ◽  
Vol 44 (4) ◽  
pp. 187-190 ◽  
Author(s):  
Anadayr L.M. SANT'ANNA ◽  
Rita de Cássia N. Cubel GARCIA ◽  
Mônica MARZOCHE ◽  
Heloisa Helena A. Gallo da ROCHA ◽  
Maria Tereza M. PAULA ◽  
...  

The prevalence of anti-human parvovirus B19 IgG antibodies was determined in sera from 165 chronic hemolytic anemia patients, receiving medical care at Instituto Estadual de Hematologia (IEHE), Rio de Janeiro, during the year of 1994. This sample represents around 10% of the chronic hemolytic anemia patients attending at IEHE. Most of these patients (140) have sickle cell disease. Anti-B19 IgG antibodies were detected in 32.1% of patients. No statistically significant difference (p > 0.05) was seen between IgG antibody prevalence in male (27.8%) and female (35.5%) patients. Anti-B19 IgG antibodies were more frequent in older (37.6%) than younger (28.2%) than 20 years old patients, although this difference had no statistical significance (p > 0.05). Anti-B19 IgG antibody prevalence showed that 67.9% of patients enrolled in the study were susceptible to B19 acute infection. With the aim to detect acute B19 infection, patients follow up continued until February 1996. During this period four patients presented transient aplastic crisis due to human parvovirus B19 as confirmed by the detection of specific IgM antibodies. All four patients were younger than 20 years old, and 3 were younger than 10 years old. Three of them were sickle cell disease patients. Three of the four acute B19 infection occurred during 1994 springtime.


2013 ◽  
Vol 17 (1) ◽  
pp. 97-101 ◽  
Author(s):  
Svetoslav Nanev Slavov ◽  
Simone Kashima ◽  
Ana Cristina Silva-Pinto ◽  
Alberto Anastacio Amarilla ◽  
Victor Hugo Aquino ◽  
...  

2017 ◽  
Vol 32 (5) ◽  
pp. 425-428 ◽  
Author(s):  
Ashraf Abdellah Saad ◽  
Ismail Beshlawi ◽  
Abdul Hakim Al-Rawas ◽  
Mathew Zachariah ◽  
Hanan Fawzy Nazir ◽  
...  

2012 ◽  
Vol 84 (10) ◽  
pp. 1652-1665 ◽  
Author(s):  
Svetoslav Nanev Slavov ◽  
Simone Kashima Haddad ◽  
Ana Cristina Silva-Pinto ◽  
Alberto Anastacio Amarilla ◽  
Helda Liz Alfonso ◽  
...  

2006 ◽  
Vol 69 (7) ◽  
pp. 1276-1280 ◽  
Author(s):  
S.H. Nasr ◽  
G.S. Markowitz ◽  
R.L. Sentman ◽  
V.D. D'agati

1996 ◽  
Vol 17 (12) ◽  
pp. 425-425

The callout on page 339 of the October issue of Pediatrics in Review should read: "Pneumococcal vaccine is recommended for children older than 2 years of age who have sickle cell disease, asplenia, nephrotic syndrome or renal failure, immunosuppression, CSF leak, or HIV infection."


Sign in / Sign up

Export Citation Format

Share Document